TY - JOUR
T1 - Cilostazol suppresses neointimal hyperplasia in canine vein grafts
AU - Kudo, Fabio A.
AU - Kondo, Yuka
AU - Muto, Akihito
AU - Miyazaki, Keiko
AU - Dardik, Alan
AU - Nishibe, Masayasu
AU - Nishibe, Toshiya
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/2
Y1 - 2009/2
N2 - Purpose: To investigate whether cilostazol, a cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitor, suppresses intimal hyperplasia in canine vein grafts, and to elucidate its mechanisms in terms of cell proliferation and apoptosis. Methods: Bilateral reversed jugular vein interposition grafts of the common carotid artery were performed in 12 beagle dogs. Starting from 7 days before surgery, either cilostazol (30 mg/day; n = 6) or a placebo (n = 6) was given orally twice daily. Vein grafts were harvested at 1 or 4 weeks, and fixed under pressure for histological examination. Results: By 1 week after implantation, the cilostazol group showed significantly less cell proliferation than the placebo group. By 4 weeks after implantation, intimal and medial thickness was significantly thinner in the cilostazol group than in the placebo group. There was significantly more apoptosis in the placebo group than in the cilostazol group at both time points. Conclusion: Cilostazol suppressed the development of intimal hyperplasia in canine autogenous vein grafts. Thus, it may be associated with the modulation of cell proliferation and apoptosis.
AB - Purpose: To investigate whether cilostazol, a cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitor, suppresses intimal hyperplasia in canine vein grafts, and to elucidate its mechanisms in terms of cell proliferation and apoptosis. Methods: Bilateral reversed jugular vein interposition grafts of the common carotid artery were performed in 12 beagle dogs. Starting from 7 days before surgery, either cilostazol (30 mg/day; n = 6) or a placebo (n = 6) was given orally twice daily. Vein grafts were harvested at 1 or 4 weeks, and fixed under pressure for histological examination. Results: By 1 week after implantation, the cilostazol group showed significantly less cell proliferation than the placebo group. By 4 weeks after implantation, intimal and medial thickness was significantly thinner in the cilostazol group than in the placebo group. There was significantly more apoptosis in the placebo group than in the cilostazol group at both time points. Conclusion: Cilostazol suppressed the development of intimal hyperplasia in canine autogenous vein grafts. Thus, it may be associated with the modulation of cell proliferation and apoptosis.
UR - http://www.scopus.com/inward/record.url?scp=59849118273&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59849118273&partnerID=8YFLogxK
U2 - 10.1007/s00595-008-3819-2
DO - 10.1007/s00595-008-3819-2
M3 - Article
C2 - 19198990
AN - SCOPUS:59849118273
SN - 0941-1291
VL - 39
SP - 128
EP - 132
JO - Surgery Today
JF - Surgery Today
IS - 2
ER -